Chemical Industry Gilead Sciences Secures Global Rights to PepStar’s Oral IL-23 Inhibitor in Landmark $1.275 Billion Deal to Transform IBD Treatment SAN FRANCISCO — In a major strategic play to expand its footprint in immunology, Gilead… Ali IkhwanOctober 24, 2026
